ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 367

Improved Fatigue-Related Quality of Life in CAPRA-2, a 12 Week Study of 5-Mg Modified (Delayed) Release Prednisone in Rheumatoid Arthritis

Rieke Alten1, Amy Grahn2, Patricia Rice3 and Frank Buttgereit4, 1Department of Internal Medicine II, Schlosspark-Klinik, University Medicine, Berlin, Germany, 2Clinical Development, Horizon Pharma, Inc, Deerfield, IL, 3Statistics, CliniRx Research, Naperville, IL, 4Charité - Universitätsmedizin Berlin, Berlin, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Fatigue, glucocorticoids, prednisolone, prednisone and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects I: Drug Studies/Drug Safety/Drug Utilization/Disease Activity & Remission

Session Type: Abstract Submissions (ACR)

Background/Purpose: Quality of life in rheumatoid arthritis (RA) patients can be improved by reducing the common symptom of fatigue caused by disease related factors such as pain and inflammation.  Recent studies indicate that glucocorticoid treatment improves patient reported fatigue (Westoff et al, 2011). Chronotherapy with a modified (delayed) release (MR) prednisone tablet may also improve these symptoms. NP01 (Horizon Pharma, Deerfield IL) is a proprietary MR formulation of prednisone that results in a 4 hour delay in traditional pharmacokinetic parameters of prednisone. This formulation capitalizes on known cytokine and endogenous biologic rhythms. Here we report fatigue scores from the Circadian Administration of Prednisone in Rheumatoid Arthritis-2 (CAPRA-2) study which evaluated patients with active RA on stable disease-modifying antirheumatic drugs (DMARDs) given MR prednisone or placebo.

Methods: The study was a 12-week, double-blind, placebo-controlled study that randomized 350 RA patients to either 5 mg MR prednisone (n=231) or placebo (n=119) taken once daily at bedtime (eg, 10pm) in addition to their standard DMARD treatment (Buttgereit et al, 2012). The primary endpoint was the proportion of patients achieving ACR20 response after 12 weeks. A secondary objective was to compare treatment with 5 mg MR prednisone and placebo in the change from baseline on the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) questionnaire. This 13 item questionnaire assesses the effect of fatigue on daily activity and function on a 5‑point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much), with a score range of 0 to 52.

Results: The mean baseline FACIT-F fatigue score was comparable in the 5 mg MR prednisone group and the placebo group (28.81 vs 28.73, Table 1). The least square mean (LSM) absolute increase from baseline to Week 12 was greater in the 5 mg MR prednisone group than in the placebo group (3.83 vs 1.59), indicating a reduction of fatigue (Table 1). The difference in FACIT-F score between baseline and Week 12 was clinically relevant for 5 mg MR prednisone but not for placebo (minimal clinically important difference [MCID]: 3-4; Cella et al, 2005). At Week 12, the LSM change from baseline was statistically significantly greater for 5 mg MR prednisone than for placebo, (LSM difference=2.24 [95% CI: 0.76, 3.72], p-value=0.0032) (Table 1). Similar results occurred for observed case data. These findings were consistent with improvement in ACR20 score.

Table 1: FACIT-F Fatigue Score at Each Visit (mITT Population, BOCF)

Visit

FACIT-F Fatigue Score

5 mg MR-Prednisone

Placebo

5 mg MR-Prednisone
vs. Placebo

Baseline

n

231

119

–

Mean (SD)

28.81 (10.443)

28.73 (10.725)

–

Week 12

n

231

119

–

Mean (SD)

32.54 (10.893)

30.25 (10.465)

–

Absolute Change from Baseline to Week 12

LSM

3.83

1.59

–

LSM Difference (SE)

–

–

2.24 (0.754)

95% CI for LSM Difference

–

–

0.76, 3.72

p-value

–

–

0.0032

Abbreviations: FACIT-F = Functional Assessment of Chronic Illness Therapy – Fatigue; mITT = modified intention-to-treat; BOCF = baseline observation carried forward; MR = modified-release; SD = standard deviation; LSM = least square mean; SE = standard error; CI = confidence interval.

Note: LSMs are from an analysis of covariance (ANCOVA) model with baseline results, treatment, and geographic region as factors. Model effects were from the Type III estimates.

Conclusion: Patients treated with 5 mg MR prednisone had significant improvement in FACIT‑F scores compared with placebo, indicating a reduction in fatigue and improvement in an important aspect of quality of life. Chronotherapy with a MR prednisone formulation improves ACR scores and provides a potential new treatment option for patients with RA that can also improve symptoms of fatigue.


Disclosure:

R. Alten,

Horizon Pharma, Inc. ,

2;

A. Grahn,

Horizon Pharma (formerly Nitec Pharma),

3;

P. Rice,

CliniRx Research Pvt. Ltd,

5;

F. Buttgereit,

Merck Serono, Horizon Pharma (formerly Nitec Pharma), Mundipharma Int. Ltd.,

5,

Merck Serono, Horizon Pharma (formerly Nitec Pharma) ,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improved-fatigue-related-quality-of-life-in-capra-2-a-12-week-study-of-5-mg-modified-delayed-release-prednisone-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology